THE DECLINE OF BCR-ABL/GUS RATIO IN CML PATIENTS TREATED UPFRONT WITH NILOTINIB SHOWS A RAPID DESCENT DURING THE FIRST TRIMESTER, AND THE RESPONSES ARE SIMILAR TO THOSE ACHIEVED WITH ABL AS CONTROL

EHA Library, Valentin Garcia-Gutierrez, 53728

AGE AND DIGITAL-PCR ANALYSIS PREDICT RELAPSES OF CML PATIENTS FOLLOWING PROGRAMMED IMATINIB INTERRUPTION IN Q-RT-PCR NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENTS

EHA Library, Silvia Mori, 53729

MR4.5 AT POST-TRANSPLANT 3 MONTHS WAS A PREDICTIVE FACTOR FOR LONG-TERM OUTCOMES IN THE PATIENTS UNDERWENT ALLOGENEIC SCT IN CML CP

EHA Library, Sung-Eun Lee, 53731

MOLECULAR MONITORING USING PERIPHERAL BLOOD COMBINED WITH BONE MARROW AT 3 MONTHS OR 6 MONTHS PROVIDES A BETTER PREDICTOR OF OUTCOMES FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Jiang Qian, 53732

BCR-ABL1 RATIO LOG REDUCTION IS A BETTER PREDICTOR OF MAJOR MOLECULAR RESPONSE (MMR) THAN 10% RATIO CUT-OFF AT 3 MONTHS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS

EHA Library, Rafael Del Orbe Barreto, 53733

GENEXPERT BCR-ABL1/ABL1 MONITOR TEST (IS) FOR ROUTINE MONITORING OF CHRONIC MYELOID LEUKEMIA PATIENTS

EHA Library, Gueorgui Balatzenko, 53734

INCREASED EXPRESSION OF INTERFERON RELATED GENES IN THE BONE MARROW MICROENVIRONMENT OF MYELODYSPLASTIC SYNDROMES

EHA Library, Miyoung Kim, 53741

ANTI-ERYTHROBLAST AUTOIMMUNITY IN EARLY MYELODYSPLASTIC SYNDROMES: ENHANCEMENT OF EPO/EPO-R SYSTEM AND PRO-APOPTOTIC EFFECT

EHA Library, Anna Zaninoni, 53746

INDEPENDENT MULTICENTRIC STUDY ON THE INTEREST OF OGATA SCORE AND OF CD5, CD7 AND CD56 IN MDS AND MDS/MPS IN REAL LIFE.

EHA Library, Estelle Guerin, 53750

IS THERE A RELATIONSHIP BETWEEN BONE MARROW CYTOMORPHOLOGY AND FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES?

EHA Library, Estelle Guerin, 53754

MOLECULAR CYTOGENETIC CHARACTERIZATION OF t(2;5)(p16.2;q33.1) LEADING TO PDGFRB/SPTBN1 GENE FUSION IN A CASE OF MDS RESPONSIVE TO IMATINIB MESYLATE

EHA Library, Daphne Koumbi, 53755

THE INTERPLAY BETWEEN OXIDATIVE STRESS AND EPIGENETIC PROFILE IN MYELOID NEOPLASIAS

EHA Library, Ana Cristina Gonçalves, 53756

THE INCIDENCE OF COMORBIDITIES AT THE TIME OF DIAGNOSIS IN PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROMES: OVERVIEW THROUGH THE 'REL' ('RETE EMATOLOGICA LOMBARDA') DISEASE REGISTRY

EHA Library, Marta Riva, 53759

MRI SURVEY IN TRANSFUSION-DEPENDENT AND NON-TRANSFUSION-DEPENDENT MDS PATIENTS

EHA Library, Alessia Pepe, 53763

CALRETICULIN MUTATION WAS RARELY DETECTED IN PATIENTS WITH MYELODYSPLASTIC SYNDROME

EHA Library, Hsin-An Hou, 53765

DEVELOPMENT OF A HIGH RESOLUTION MELTING CURVE ANALYSIS SCREENING TEST FOR SRSF2 SPLICING FACTOR GENE MUTATIONS.

EHA Library, Eduardo Garza, 53768

GLUTATHIONE S-TRANSFERASE P1 (GSTP1) PROMOTER HYPERMETHYLATION IN MDS

EHA Library, Constantina Sambani, 53770

IDENTIFICATION OF NOVEL ALTERNATIVE SPLICE VARIANTS OF SIRTUINS IN MULTIPLE MYELOMA: A BIOLOGICALLY RELEVANT INDICATOR OF POOR OUTCOME

EHA Library, Michele Cea, 53773

ACTIVATED AND EXPANDED NATURAL KILLER (NKAE) CELLS KILL MULTIPLE MYELOMA (MM) CLONOGENIC PLASMA CELLS THROUGH NKG2D AND NKP30 RECEPTORS AND THEIR LIGANDS

EHA Library, Alejandra Leivas, 53778

CIRCULATING MIR-34A AND MIR-130A AS BIOMARKERS OF EXTRAMEDULLARY DISEASE

EHA Library, Lenka Kubiczkova, 53779

GENE EXPRESSION PROFILING AND COPY NUMBER ALTERATIONS OF CIRCULATING CLONOTYPIC B CELLS OF MULTIPLE MYELOMA NEWLY DIAGNOSED PATIENTS REVEALS PATHWAYS POTENTIALLY INVOLVED IN THE DISEASE PERSISTENCE

EHA Library, Marina Martello, 53782

DOWNREGULATION OF TELOMERASE ACTIVITY IN RESPONSE TO NEW GENERATION OF PROTEASOME INHIBITORS (EPOXOMICIN AND MG132) IN MULTIPLE MYELOMA CELLS

EHA Library, Eli Muchtar, 53786

HSP90 INHIBITOR-DRUG CONJUGATES (HDC) WITH ANTITUMOR AGENTS TARGETING HEMATOLOGICAL MALIGNANCES

EHA Library, Patricia Rao, 53787

POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN LENALIDOMIDE-REFRACTORY AND PROTEASOME INHIBITOR-EXPOSED MYELOMA: THE MM-005 TRIAL

EHA Library, PAUL RICHARDSON, 53797

Preliminary pre-randomization results from a phase 3 study of front-line subcutaneous bortezomib-based induction and consolidation in transplantation-eligible multiple myeloma patients

EHA Library, Noemi Horvath, 53799

GERIATRIC ASSESSMENT PREDICTS SURVIVAL AND RISK OF SERIOUS ADVERSE EVENTS FOR ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.

EHA Library, Roberto Mina, 53800

EFFICACY AND SAFETY OF THREE SUBCUTANEOUS BORTEZOMIB COMBINATIONS IN ELDERLY, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Chiara Cerrato, 53803

PRELIMINARY SAFETY AND EFFICACY OF TH-302, AN INVESTIGATIONAL HYPOXIA-TARGETED DRUG, AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR MM)

EHA Library, PAUL RICHARDSON, 53806

POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) WITH DELETION DEL(17P) AND/OR TRANSLOCATION T(4;14).

EHA Library, Xavier Leleu, 53807

HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): THE FIRST TRIAL

EHA Library, Michel Delforge, 53809

MM-003, A PHASE 3 STUDY OF POMALIDOMIDE + LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: OUTCOMES BY PRIOR THERAPY AND RESPONSE DEPTH

EHA Library, Jesús San Miguel, 53810

OUTCOMES OF PRIMARY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS IN PATIENTS TREATED UPFRONT WITH BORTEZOMIB OR LENALIDOMIDE AND THE IMPORTANCE OF RISK ADAPTED STRATEGIES

EHA Library, Efstathios Kastritis, 53812

BORTEZOMIB COMBINATION THERAPY, AND SUBSEQUENT BORTEZOMIB RE-TREATMENT, IS A USEFUL TREATMENT STRATEGY FOR MULTIPLE MYELOMA PATIENTS WITH RAS MUTATIONS

EHA Library, Dean Smith, 53813

Long-term follow-up of a randomized phase 2 study of bortezomib, thalidomide, and dexamethasone, with or without cyclophosphamide, as induction therapy for patients with previously untreated multiple myeloma

EHA Library, Heinz Ludwig, 53815

A PHASE 1 STUDY OF FILANESIB (ARRY-520) WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE (DEX) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Ajai Chari, 53816

A PHASE IB DOSE ESCALATION TRIAL OF SAR650984 (ANTI-CD-38 MAB) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Thomas Martin, 53819

Monoclonal gammopathy of undetermined significance is associated with inferior survival: a population-based study

EHA Library, Ebba Lindqvist, 53821

INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Kai Riecke, 53822

BORTEZOMIB OR THALIDOMIDE INCORPORATED INTO AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS NOVEL AGENT-BASED TREATMENTS FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A CASE-MATCH COMPARISON

EHA Library, Paola Tacchetti, 53825

GATA1 IS OVEREXPRESSED IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND IT IS NORMALIZED BY ANAGRELIDE TREATMENT.

EHA Library, Ciro Rinaldi, 53838

IMPORTANCE OF CALR MUTATIONS IN THE DIAGNOSIS OF PRIMARY MYELOFIBROSIS.

EHA Library, Lurdes Zamora Plana, 53839

MOUSE LEUKEMIC TRANSFORMATION IN PMF XENOGRAFT MODEL REVEALS PARACRINE REGULATION IN DISEASE PROGRESSION

EHA Library, Ioanna Triviai, 53841

DEREGULATION OF MICRORNA146B-1 IS ASSOCIATED WITH MYELOFIBROSIS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jung Sook Ha, 53844

HIGH THROUGHPUT SCREENING ON PERIPHERAL BLOOD CD34 CELLS WITH A FLOW CYTOMETRY AUTOMATED PLATFORM (EXVITECH), TO IDENTIFY SENSITIVITY TO RUXOLITINIB IN MYELOFIBROSIS PATIENTS

EHA Library, Alicia Arenas, 53845

HEMATOPOIETIC PROGENITOR CELLS EXPRESSING VE-CADHERIN ARE DETECTABLE IN THE SPLEEN OF PATIENTS WITH MYELOFIBROSIS AND ARE IN CLOSE CONTACT WITH MICROVESSELS

EHA Library, Vittorio Rosti, 53846

EVALUATION OF THE ASSOCIATION BETWEEN JAK2 46/1 HAPLOTYPE AND MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jung Sook Ha, 53847

OUTCOME OF JAK2/MPL/CALR TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Victoria Panagiota, 53850

INFLUENCE OF IL-28B AND IL-6 GENETIC POLYMORPHISM ON IFN-ALFA TREATMENT OUTCOME IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL TROMBOCYTHEMIA

EHA Library, Marie Lindgren, 53858

DYNAMICS OF CALR MUTANT ALLELE BURDEN IN ESSENTIAL THROMBOCYTHEMIA PATIENTS

EHA Library, Beatriz Bellosillo, 53859

RESPONSE TO RUXOLITINIB IN PATIENTS WITH INTERMEDIATE-1, INTERMEDIATE-2 AND HIGH-RISK MYELOFIBROSIS: RESULTS OF THE UK ROBUST TRIAL

EHA Library, Adam Mead, 53860

EARLY RESPONSE OF RADOTINIB THERAPY MAY PREDICT LONG-TERM OUTCOMES IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH RESISTANCE OR INTOLERANCE TO BCR-ABL1 TKIS: 24 MONTH UPDATE OF PHASE 2 TRIAL

EHA Library, Sung-Hyun Kim, 53730

CHANGES OF QUALITY OF LIFE AFTER CESSATION OF IMATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH UNDETECTABLE MOLECULAR RESIDUAL DISEASE

EHA Library, Sukjoong Oh, 53737

LENALIDOMIDE MODIFIES THE BEHAVIOR OF MESENCHYMAL STROMAL CELLS (MSC) FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITH 5Q- (MDS-5Q-)

EHA Library, Sandra Muntion, 53739

IMPAIRED LINEAGE PRIMING AND PROLIFERATIVE POTENTIAL OF BONE MARROW MESENCHYMAL STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES ARE ASSOCIATED WITH ABNORMAL WNT SIGNALING PATHWAY

EHA Library, Charalampos Pontikoglou, 53740

CHROMOTHRIPSIS IN BONE MARROW CELLS OF ADULT PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) WITH COMPLEX KARYOTYPES.

EHA Library, Zuzana Zemanova, 53743

CIRCULATING SERUM MICRORNA-21 PREDICTS SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Jung Yeon Lee, 53745

POSSIBLE PREVENTIVE ROLE OF CXCR4 AND ACTIVE CASPASE 3 IN LEUKEMIC EVOLUTION OF MYELODYSPLASTIC SYNDROMES

EHA Library, Veselka Nikolova, 53752

NEW GERMLINE TERT GENE MUTATIONS IN APLASTIC ANEMIA / HYPOCELLULAR MYELODYSPLASTIC SYNDROMES

EHA Library, Caterina Matteucci, 53753

IMMUNE SURVEILLANCE IMPACTS PROGNOSIS: REGULATORY T CELLS AND PROGENITOR B CELLS ARE INDEPENDENT PREDICTORS OF SURVIVAL IN LOW AND INTERMEDIATE RISK MDS

EHA Library, Josephine Kahn, 53757

DEFERASIROX CHELATION THERAPY IN TRANSFUSION DEPENDENT MDS PATIENTS. A 'REAL WORLD' REPORT FROM TWO REGIONAL ITALIAN REGISTRIES : GRUPPO ROMANO MIELODISPLASIE AND REGISTRO BASILICATA

EHA Library, Luca Maurillo, 53758

MYOCARDIAL TISSUE CHARACTERIZATION BY CARDIAC MR IMAGING IN MYELODYSPLASTIC SYNDROMES

EHA Library, Alessia Pepe, 53760

PRE AND POST-TREATMENT SERUM FERRITIN LEVELS IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES RECEIVING ERYTHROPOIESIS STIMULATING AGENTS

EHA Library, Heather Leitch, 53761

VALIDATION OF LOW RISK PROGNOSTIC SCORING SYSTEM (LR-PSS) IN 318 PATIENTS WITH LOWER RISK IPSS MYELODYSPLASTIC SYNDROME FROM A SINGLE CENTER.

EHA Library, Helena Pomares Marin, 53762

THE IMPACT OF TRANSFUSION DEPENDENCY ON THE OUTCOME OF PATIENTS WITH VERY LOW AND LOW RISK MYELODYSPLASTIC SYNDROME ACCORDING TO THE IPSS-R.

EHA Library, Montserrat Arnan, 53764

DAPK AND TRAIL RECEPTORS METHYLATION STATUS IN MYELODYSPLASTIC SYNDROMES PATIENTS

EHA Library, Ana Cristina Gonçalves, 53772

BONE MARROW CD14+ CELLS SHOW DIFFERENT TRANSCRIPTIONAL PROFILES IN MULTIPLE MYELOMA (MM) AS COMPARED TO SMOLDERING MM AND MGUS: OVEREXPRESSION OF IL-21R AND ITS INVOLVEMENT IN OSTEOCLASTOGENESIS.

EHA Library, Nicola Giuliani, 53774

LONG-TERM RESULTS OF THE GIMEMA VEL-03-096 TRIAL IN MULTIPLE MYELOMA PATIENTS RECEIVING VTD CONSOLIDATION AFTER ASCT: IMPACT OF MRD KINETICS ON DURATION OF RESPONSE AND OVERALL SURVIVAL

EHA Library, Simone Ferrero, 53776

DOES CHARACTERISTIC PHENOTYPE FOR PLASMA CELL LEUKAEMIA EXIST?

EHA Library, Lucie Rihova, 53781

CAN GENOME ARRAY SCREENING REPLACE FISH AS A FRONT-LINE TEST IN MULTIPLE MYELOMA?

EHA Library, Katya Gancheva, 53783

COMPARATIVE STUDY OF GENE EXPRESSION PROFILING BETWEEN ASYMPTOMATIC AND SYMPTOMATIC WALDENSTROM\'S MACROGLOBULINEMIA PATIENTS

EHA Library, Cristina Jimenez, 53784

TRANSCRIPTIONAL REGULATION OF ALTERNATE SPLICING BY DP1 AND THEIR FUNCTIONAL IMPACT IN MULTIPLE MYELOMA

EHA Library, Mariateresa Fulciniti, 53785

TOLL-LIKE RECEPTOR ACTIVATION PROMOTES MULTIPLE MYELOMA CELL GROWTH AND SURVIVAL BY SUPPRESSION OF ENDOPLASMIC RETICULUM STRESS FACTOR CHOP

EHA Library, Efstathios Kastritis, 53788

ENDOPLASMIC RETICULUM STRESS-RELATED GENE EXPRESSION CAN PREDICT RESPONSE TO BORTEZOMIB IN MYELOMA

EHA Library, Narita Tomoko, 53789

MODIFYING DNA REPAIR PATHWAYS IN CHEMOTHERAPY BY GENOTOXIC DRUGS – TOWARDS PERSONALIZED MYELOMA THERAPY

EHA Library, Maria Gkotzamanidou, 53790

TARGETING ANGIOGENESIS IN MULTIPLE MYELOMA: A POSSIBLE ROLE FOR EPHA3 AND A SPECIFIC MONOCLONAL ANTIBODY

EHA Library, Antonella Caivano, 53792

INITIAL RESULTS FROM A PHASE 2 STUDY OF CARFILZOMIB, LENALIDOMIDE, AND LOW-DOSE DEXAMETHASONE (KRD) PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

EHA Library, Andrzej J. Jakubowiak, 53793

THE USE OF SINGLE AGENT ZOLEDRONIC ACID PREVENTS THE DEVELOPMENT OF BONE DISEASE COMPLICATIONS IN MYELOMA PATIENTS WITH ASYMPTOMATIC RELAPSES WITH NO DEMONSTRATED EFFECT ON SYMPTOMS PROGRESSION

EHA Library, Ramon Garcia-Sanz, 53794

LENALIDOMIDE-DEXAMETHSONE (RD) VS MELPHALAN-LENALIDOMIDE-PREDNISONE (MPR) VS CYCLOPHOSPHAMIDE-PREDNISONE-LENALIDOMIDE (CPR) IN ELDERLY COMMUNITY-BASED NEWLY DIAGNOSED MYELOMA PATIENTS

EHA Library, Valeria Magarotto, 53795

SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA.

EHA Library, Torben Plesner, 53796

Oral investigational proteasome inhibitor ixazomib plus lenalidomide-dexamethasone in elderly patients with previously untreated multiple myeloma

EHA Library, PAUL RICHARDSON, 53801

DOSE-DEPENDENT EFFICACY OF DARATUMUMAB AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Henk Lokhorst, 53802

RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HISTONE DEACETYLASE 6 INHIBITOR, IS ACTIVE AND WELL TOLDERATED IN COMBINATION WITH LENALIDOMIDE OR BORTEZOMIB IN PATIENTS WITH REFRACTORY MYELOMA

EHA Library, Noopur Raje, 53804

A PHASE 2 STUDY OF CIRCULARLY PERMUTED TRAIL (CPT) PLUS THALIDOMIDE AND DEXAMETHASONE VERSUS THALIDOMIDE AND DEXAMETHASON IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Wenming Chen, 53805

PERSISTENT PFS BENEFIT AND SUPERIOR PFS2 WITH VTD VS TD FOR NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE, MULTIPLE MYELOMA (MM) PATIENTS: UPDATED ANALYSIS OF GIMEMA MMY-3006 STUDY

EHA Library, Michele Cavo, 53808

EUROPEAN POST-APPROVAL SAFETY STUDY (PASS) OF RELAPSE/REFRACTORY MULTIPLE MYELOMA (RRMM): PATTERNS OF ANTITHROMBOTIC PROPHYLAXIS IN A LARGE COHORT OF MM PATIENTS TREATED WITH LENALIDOMIDE

EHA Library, Barbara Gamberi, 53814

MULTIPLE MYELOMA PATIENTS THAT DEVELOP SECOND PRIMARY MALIGNANCY HAVE A WORSE PROGNOSIS THAN MULTIPLE MYELOMA PATIENTS TREATED BEFORE THE INTRODUCTION OF NOVEL AGENTS: A POPULATION BASED-STUDY

EHA Library, Gudbjörg Jónsdóttir, 53824

INTRACELLULAR CALCIUM DEPOSITS AND STORE OPERATED CALCIUM ENTRY IN CD34+ CELLS FROM PATIENTS WITH MYELOFIBROSIS CARRYING A CALR MUTATION

EHA Library, Vittorio Rosti, 53834

VEGF-INDUCED CA2+ SIGNALS ARE DERANGED IN ENDOTHELIAL PROGENITOR CELLS FROM PATIENTS WITH MYELOFIBROSIS CARRYING JAK2 MUTATIONS

EHA Library, Francesco Moccia, 53835

LOW RATE OF CALR MUTATIONS IN REFRACTORY ANAEMIA WITH RING SIDEROBLASTS AND MARKED THROMBOCYTOSIS

EHA Library, Francois Girodon, 53837

CYTOGENETIC INVESTIGATION OF G-CSF-STIMULATED PERIPHERAL BLOOD IN PATIENTS WITH PRIMARY MYELOFIBROSIS

EHA Library, Rostyslav Lozynskyy, 53842

CHARACTERIZATION OF MPL-MUTATED MYELOID NEOPLASMS: A REVIEW OF 224 MPL+ CASES

EHA Library, Keming Lin, 53843

CLINICAL CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASM WITH CALRETICULIN MUTATIONS

EHA Library, Tunde Krahling, 53854

JAK2 V617F ALLELE BURDEN AND VASCULAR COMPLICATION OCCURRENCE RISK IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Martyna Borowczyk, 53855

RUXOLITINIB PLUS PANOBINOSTAT IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST–POLYCYTHEMIA VERA MYELOFIBROSIS OR POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A PHASE 1B DOSE-FINDING STUDY

EHA Library, Alessandro M. Vannucchi, 53856

UTILITY OF BONE MARROW HISTOLOGY AND IMMUNOHISTOCHEMISTRY IN THE DIAGNOSTIC WORK-UP OF EOSINOPHILIA OF UNKNOWN SIGNIFICANCE

EHA Library, Georgia Metzgeroth, 53857

TREATMENT OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS WITH PEGYLATED INTERFERON ALPHA-2A: A PROSPECTIVE MONOCENTER COHORT STUDY.

EHA Library, Valerio De Stefano, 53861

SPECIFIC DETECTION OF CALR-MUTATED MYELOPROLIFERATIVE NEOPLASMS BY IMMUNOSTAINING

EHA Library, Giada Rotunno, 53862

MICROARRAY ANALYSIS OF CHROMOSOME 11Q IN A GROUP OF AGGRESSIVE LYMPHOMA: THE PARTIAL DUPLICATION OF 11Q AS A CYTOGENETIC MARKER OF SUBSET OF THE GREY ZONE BETWEEN BURKITT'S (BL) AND DIFFUSE LARGE B-C

EHA Library, Beata Grygalewicz, 53864

CLONAL EVOLUTION IN BURKITT LYMPHOMA/LEUKEMIA

EHA Library, Sietse Aukema, 53867